Ramn Garca-Sanz

List of Publications by Year in Descending Order

320 papers	16,203 citations	63 h-index	119 g-index
342 ext. papers	18,917 ext. citations	5.3 avg, IF	5.66 L-index

#	Paper	IF	Citations
320	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.. *Leukemia and Lymphoma*, **2022**, 1-12	1.9	0
319	Preneoplastic somatic mutations including in lymphoplasmacytic lymphoma.. *Science Advances*, **2022**, 8, eabl4644	14.3	4
318	Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102321	2.2	4
317	A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.. *Clinical and Translational Oncology*, **2022**, 1	3.6	
316	RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation.. *Experimental Hematology and Oncology*, **2022**, 11, 18	7.8	0
315	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.. *American Journal of Hematology*, **2022**,	7.1	2
314	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 68	7	0
313	MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. *International Journal of Molecular Sciences*, **2022**, 23, 5570	6.3	1
312	Booster effect after SARS-CoV-2 vaccination in hematological immunocompromised patients with prior COVID-19.. *Blood Advances*, **2021**,	7.8	1
311	COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP. *Blood Advances*, **2021**,	7.8	3
310	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. *Blood Advances*, **2021**, 5, 3188-3198	7.8	1
309	Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial. *Blood*, **2021**, 138, 2459-2459	2.2	
308	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. *Haematologica*, **2021**, 106, 2940-2946	6.6	4
307	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. *Journal of Clinical Oncology*, **2021**, JCO2100838	2.2	9
306	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). *Journal of Hematology and Oncology*, **2021**, 14, 168	22.4	24
305	Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. *Cancers*, **2021**, 13,	6.6	6
304	Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström's Macroglobulinemia-A Particularly Heterogeneous Lymphoma. *Cancers*, **2021**, 13,	6.6	3

303	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e119-e130	21.7	33
302	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. *International Journal of Cancer*, **2021**, 149, 327-336	7.5	1
301	Genetically determined telomere length and multiple myeloma risk and outcome. *Blood Cancer Journal*, **2021**, 11, 74	7	2
300	Impact of the COVID-19 pandemic on the care of cancer patients in Spain. *ESMO Open*, **2021**, 6, 100157	6	13
299	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping. *British Journal of Haematology*, **2021**, 195, 542-551	4.5	1
298	Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival. *International Journal of Cancer*, **2021**, 148, 1887-1894	7.5	1
297	6q deletion in Waldenstrm macroglobulinaemia negatively affects time to transformation and survival. *British Journal of Haematology*, **2021**, 192, 843-852	4.5	7
296	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. *Blood*, **2021**, 137, 49-60	2.2	28
295	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. *Blood Cancer Journal*, **2021**, 11, 11	7	0
294	Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. *Blood Advances*, **2021**, 5, 725-736	7.8	7
293	Waldenstrm's Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy. *Journal of Blood Medicine*, **2021**, 12, 795-807	2.3	1
292	Allele and haplotype frequencies of HLA-A, -B, -C, -DRB1, -DQB1 and -DQA1 in Castile and Leon region from North West of Spain. *Human Immunology*, **2021**, 82, 549-550	2.3	0
291	Management of mixed acute rejection driven by a donor-specific complement-binding anti-DQB1*03:01 antibody and intraepithelial CD8 T-cells in a kidney recipient: a case report. *British Journal of Biomedical Science*, **2021**, 78, 244-247	1.6	
290	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. *Cancers*, **2020**, 12,	6.6	6
289	Zanubrutinib for the treatment of MYD88 wild-type Waldenstrm macroglobulinemia: a substudy of the phase 3 ASPEN trial. *Blood Advances*, **2020**, 4, 6009-6018	7.8	20
288	Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression. *Cellular Oncology (Dordrecht)*, **2020**, 43, 743-750	7.2	2
287	FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 4171-4182	5.6	14
286	Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. *British Journal of Haematology*, **2020**, 189, 718-730	4.5	6

285	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. *Blood Cancer Journal*, **2020**, 10, 14	7	3
284	Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1534-1542	4.7	9
283	Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. *British Journal of Haematology*, **2020**, 189, 1165-1170	4.5	15
282	Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design. *PLoS ONE*, **2020**, 15, e0227986	3.7	15
281	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. *Blood*, **2020**, 135, 2375-2387	2.2	11
280	Reply to Brown et´al: 'Correct application of variant classification guidelines in germline mutated disorders to assist clinical diagnosis'. *Leukemia and Lymphoma*, **2020**, 61, 248-249	1.9	
279	Current functioning of cardio-oncology units in Spain. *Clinical and Translational Oncology*, **2020**, 22, 1418-1422	3.4	4
278	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 784-792	2.2	94
277	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. *Blood*, **2020**, 136, 2038-2050	2.2	110
276	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, **2020**, 136, 2401-2409	2.2	38
275	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 108	7	20
274	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. *Blood Advances*, **2020**, 4, 6023-6033	7.8	4
273	A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients. *Journal of Molecular Diagnostics*, **2020**, 22, 60-71	5.1	5
272	Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited mutations without a pre-existing platelet disorder. *Leukemia and Lymphoma*, **2020**, 61, 181-184	1.9	3
271	Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). *Annals of Oncology*, **2019**, 30, 612-620	19.3	47
270	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. *Blood Cancer Journal*, **2019**, 9, 52	7	4
269	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. *Leukemia*, **2019**, 33, 2254-2265	10.7	45
268	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. *Lancet Oncology, The*, **2019**, 20, e302-e312	21.7	166

267	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. *Leukemia*, **2019**, 33, 2324-2330	10.7	18
266	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. *Leukemia*, **2019**, 33, 2241-2253	10.7	92
265	Abordaje de la fibrilaci□ auricular en pacientes con c□cer activo. Documento de consenso de expertos y recomendaciones. *Revista Espanola De Cardiologia*, **2019**, 72, 749-759	1.5	5
264	PS1352 DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS. *HemaSphere*, **2019**, 3, 617-618	0.3	1
263	Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. *Blood Cancer Journal*, **2019**, 9, 90	7	7
262	Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. *Hematological Oncology*, **2019**, 37, 215-218	1.3	1
261	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. *Lancet Oncology, The*, **2018**, 19, 370-381	21.7	216
260	Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. *Annals of Hematology*, **2018**, 97, 475-484	3	6
259	Highly sensitive mutation detection by droplet digital polymerase chain reaction in Waldenstr□m macroglobulinemia. *Haematologica*, **2018**, 103, 1029-1037	6.6	32
258	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. *Haematologica*, **2018**, 103, 880-889	6.6	8
257	A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. *Journal of Medical Economics*, **2018**, 21, 525-536	2.4	14
256	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. *Haematologica*, **2018**, 103, e544-e548	6.6	9
255	VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data. *Blood*, **2018**, 132, 4446-4446	2.2	1
254	A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. *Blood*, **2018**, 132, 1620-1620	2.2	12
253	Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). *Blood Cancer Journal*, **2018**, 8, 117	7	35
252	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. *PLoS ONE*, **2018**, 13, e0203392	3.7	10
251	A safety profile of medications used to treat Waldenstr□m's macroglobulinemia. *Expert Opinion on Drug Safety*, **2018**, 17, 609-621	4.1	2
250	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr□m's Macroglobulinemia. *New England Journal of Medicine*, **2018**, 378, 2399-2410	59.2	189

249	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. *Lancet Haematology,the*, **2018**, 5, e299-e309	14.6	24
248	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. *Leukemia*, **2017**, 31, 2094-2103	10.7	298
247	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. *Haematologica*, **2017**, 102, 160-167	6.6	32
246	Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. *Leukemia*, **2017**, 31, 1446-1449	10.7	35
245	Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. *Haematologica*, **2017**, 102, 922-931	6.6	22
244	Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1598-1604	5.9	6
243	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 241-250	21.7	159
242	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. *Blood*, **2017**, 129, 456-459	2.2	40
241	From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. *Blood Cancer Journal*, **2017**, 7, e591	7	14
240	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. *Clinical Cancer Research*, **2017**, 23, 6602-6615	12.9	19
239	Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma. *Annals of Hematology*, **2017**, 96, 1699-1705	3	5
238	DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. *Journal of Hematology and Oncology*, **2017**, 10, 92	22.4	19
237	The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. *Leukemia and Lymphoma*, **2017**, 58, 1144-1152	1.9	16
236	A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. *Journal of Molecular Diagnostics*, **2017**, 19, 99-106	5.1	16
235	Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50´years. *Annals of Hematology*, **2017**, 96, 9-16	3	11
234	Identification of miRSNPs associated with the risk of multiple myeloma. *International Journal of Cancer*, **2017**, 140, 526-534	7.5	6
233	Waldenström Macroglobulinemia Immunophenotype **2017**, 21-34		0
232	The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia. *Leukemia*, **2017**, 31, 747-751	10.7	19

231	Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. *Bone Marrow Transplantation*, **2017**, 52, 567-569	4.4	4
230	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. *Hematological Oncology*, **2017**, 35, 746-751	1.3	17
229	Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. *Thrombosis and Haemostasis*, **2017**, 117, 66-74	7	27
228	HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. *PLoS ONE*, **2017**, 12, e0172978	3.7	2
227	Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. *Clinical Cancer Research*, **2016**, 22, 207-17	12.9	18
226	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. *British Journal of Haematology*, **2016**, 175, 77-86	4.5	41
225	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). *American Journal of Hematology*, **2016**, 91, 806-11	7.1	7
224	Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. *British Journal of Haematology*, **2016**, 174, 859-67	4.5	12
223	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. *Annals of Hematology*, **2016**, 95, 253-62	3	14
222	Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). *Blood*, **2016**, 128, 1109-1109	2.2	21
221	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. *Blood*, **2016**, 128, 2957-2957	2.2	1
220	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. *Blood*, **2016**, 128, 3283-3283	2.2	2
219	Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. *Blood*, **2016**, 128, 4503-4503	2.2	2
218	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. *Oncotarget*, **2016**, 7, 59029-59048	3.3	14
217	Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse. *Oncotarget*, **2016**, 7, 80664-80679	3.3	10
216	Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial. *Blood*, **2016**, 128, 2078-2078	2.2	
215	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. *Blood*, **2016**, 128, 375-375	2.2	1
214	Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone. *Case Reports in Hematology*, **2016**, 2016, 3947510	0.7	3

213	Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. *British Journal of Haematology*, **2016**, 172, 709-15	4.5	60
212	Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders. *Haemophilia*, **2016**, 22, 590-7	3.3	34
211	Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. *Clinical Case Reports (discontinued)*, **2016**, 4, 1096-1100	0.7	1
210	Primary amyloidosis. *Medicina Clínica (English Edition)*, **2016**, 147, 121-126	0.3	
209	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. *Leukemia*, **2016**, 30, 2026-2031	10.7	17
208	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. *Blood*, **2016**, 127, 1896-906	2.2	65
207	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. *Blood*, **2016**, 128, 1321-8	2.2	125
206	WM, MYD88, and CXCR4: following the thread. *Blood*, **2016**, 128, 746-8	2.2	13
205	Multiple Myeloma Minimal Residual Disease. *Cancer Treatment and Research*, **2016**, 169, 103-122	3.5	12
204	Origin of Waldenstrom's macroglobulinaemia. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 136-147	4.2	9
203	Treatment for patients with newly diagnosed multiple myeloma in 2015. *Blood Reviews*, **2015**, 29, 387-403	11.1	44
202	A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. *Acta Oncológica*, **2015**, 54, 933-8	3.2	11
201	The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. *Leukemia*, **2015**, 29, 1435-7	10.7	14
200	Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?. *Clinical Cancer Research*, **2015**, 21, 2001-8	12.9	32
199	Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. *Haematologica*, **2015**, 100, 1207-13	6.6	15
198	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 2039-2051	4.7	114
197	Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. *Haematologica*, **2015**, 100, e289-91	6.6	10
196	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. *Endocrine-Related Cancer*, **2015**, 22, 545-59	5.7	10

195	Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2015**, 1849, 353-66	6	21
194	Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. *Leukemia*, **2015**, 29, 1186-94	10.7	52
193	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. *International Journal of Cancer*, **2015**, 136, E351-8	7.5	23
192	The cellular origin and malignant transformation of Waldenström macroglobulinemia. *Blood*, **2015**, 125, 2370-80	2.2	51
191	The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. *Haematologica*, **2015**, 100, e53-5	6.6	35
190	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. *Blood*, **2015**, 126, 1411-1411	2.2	1
189	Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia. *Blood*, **2015**, 126, 2096-2096	2.2	3
188	Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM). *Blood*, **2015**, 126, 2745-2745	2.2	12
187	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. *Blood*, **2015**, 126, 2962-2962	2.2	1
186	Genetic Characterization of Waldenstrom Macroglobulinemia By Next Generation Sequencing: An Analysis of Fouteen Genes in a Series of 61 Patients. *Blood*, **2015**, 126, 2971-2971	2.2	2
185	Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). *Blood*, **2015**, 126, 367-367	2.2	2
184	Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). *Blood*, **2015**, 126, 582-582	2.2	13
183	Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma. *Blood*, **2015**, 126, 2972-2972	2.2	
182	Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 670-4	4	11
181	International Myeloma Working Group recommendations for global myeloma care. *Leukemia*, **2014**, 28, 981-92	10.7	132
180	Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. *Blood*, **2014**, 124, 1300-3	2.2	52
179	ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. *Annals of Hematology*, **2014**, 93, 1745-53	3	25
178	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. *Blood*, **2014**, 123, 3073-9	2.2	306

177	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. *Blood*, **2014**, 123, 4120-31	2.2	150
176	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. *Blood*, **2014**, 124, 1404-11	2.2	107
175	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. *Haematologica*, **2014**, 99, 1114-22	6.6	35
174	Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines. *PLoS ONE*, **2014**, 9, e92378	3.7	22
173	Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification. *Leukemia*, **2014**, 28, 166-73	10.7	57
172	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. *Haematologica*, **2014**, 99, 155-62	6.6	23
171	Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. *Haematologica*, **2014**, 99, 1365-72	6.6	48
170	Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. *Applied Immunohistochemistry and Molecular Morphology*, **2014**, 22, 768-73	1.9	22
169	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. *Leukemia*, **2014**, 28, 391-7	10.7	129
168	Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. *Leukemia*, **2014**, 28, 384-390	10.7	202
167	Bence Jones Proteinuria in Smoldering Multiple Myeloma As Predictor Marker of Progression to Symptomatic Multiple Myeloma. *Blood*, **2014**, 124, 3369-3369	2.2	2
166	A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, TPS8628-TPS8628	2.2	
165	Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium. *Blood*, **2014**, 124, 2044-2044	2.2	
164	Intraclonal Heterogeneity Associates with Clonal Stability in Multiple Myeloma. *Blood*, **2014**, 124, 3412-3412	2.2	
163	The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis. *Blood*, **2014**, 124, 3421-3421	2.2	
162	Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma. *Blood*, **2014**, 124, 2001-2001	2.2	1
161	The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. *Annals of Hematology*, **2013**, 92, 97-100	3	16
160	Kikuchi-Fujimoto disease: a case supporting a role for human herpesvirus 7 involvement in the pathogenesis. *Rheumatology International*, **2013**, 33, 3065-8	3.6	5

159	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. *Journal of Clinical Oncology*, **2013**, 31, 2347-57	2.2	245
158	Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). *Blood*, **2013**, 122, 3276-82	2.2	135
157	Response assessment in Waldenstr□h macroglobulinaemia: update from the VIth International Workshop. *British Journal of Haematology*, **2013**, 160, 171-6	4.5	173
156	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. *Journal of Human Genetics*, **2013**, 58, 155-9	4.3	5
155	Prognosis and Staging of Multiple Myeloma **2013**, 615-636		2
154	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr□'s macroglobulinemia. *Leukemia*, **2013**, 27, 1722-8	10.7	179
153	Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. *Haematologica*, **2013**, 98, 640-8	6.6	68
152	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. *British Journal of Haematology*, **2013**, 163, 223-34	4.5	5
151	Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. *British Journal of Haematology*, **2013**, 163, 581-9	4.5	25
150	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. *Blood*, **2013**, 122, 1448-54	2.2	18
149	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. *Blood*, **2013**, 122, 3591-8	2.2	98
148	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. *Haematologica*, **2013**, 98, 79-86	6.6	96
147	A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology. *Blood*, **2013**, 122, 272-272	2.2	3
146	Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS. *Blood*, **2013**, 122, 400-400	2.2	
145	Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL). *Blood*, **2013**, 122, 1841-1841	2.2	
144	Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs). *Blood*, **2013**, 122, 402-402	2.2	
143	The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. *European Journal of Haematology*, **2012**, 88, 450-4	3.8	26
142	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. *British Journal of Haematology*, **2012**, 157, 331-8	4.5	12

141	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. *Haematologica*, **2012**, 97, 616-21	6.6	15
140	Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma. *European Journal of Haematology*, **2012**, 89, 328-35	3.8	13
139	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. *British Journal of Haematology*, **2012**, 158, 805-9	4.5	18
138	Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. *Blood*, **2012**, 120, 2581-8	2.2	129
137	Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. *Annals of Hematology*, **2012**, 91, 1887-95	3	9
136	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580
135	Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. *American Journal of Pathology*, **2012**, 181, 1879-88	5.8	24
134	Capillary electrophoresis single-strand conformation analysis (CE-SSCA) for clonality detection in lymphoproliferative disorders. *Journal of Hematopathology*, **2012**, 5, 83-89	0.4	1
133	Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). *International Journal of Oncology*, **2012**, 40, 625-38	4.4	7
132	Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. *Leukemia and Lymphoma*, **2012**, 53, 812-9	1.9	13
131	Genomic analysis of high-risk smoldering multiple myeloma. *Haematologica*, **2012**, 97, 1439-43	6.6	37
130	EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. *Leukemia*, **2012**, 26, 2159-71	10.7	308
129	Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. *Leukemia*, **2012**, 26, 1419-22	10.7	13
128	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. *Leukemia*, **2012**, 26, 2521-9	10.7	81
127	Multiple myeloma: treatment evolution. *Hematology*, **2012**, 17 Suppl 1, S3-6	2.2	11
126	Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 93-5	2	9
125	Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 168-71	2	12
124	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. *Haematologica*, **2011**, 96, 468-71	6.6	28

123	The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. *Blood*, **2011**, 117, 3613-6	2.2	52
122	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. *Blood*, **2011**, 118, 4547-53	2.2	52
121	Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y Leó (northwest-central Spain). *Tissue Antigens*, **2011**, 78, 249-55		13
120	Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation. *Annals of Hematology*, **2011**, 90, 227-9	3	0
119	The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. *Clinical Cancer Research*, **2011**, 17, 1692-700	12.9	100
118	Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation. *Clinics and Practice*, **2011**, 1, e95	2.4	6
117	Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. *British Journal of Haematology*, **2010**, 148, 110-4	4.5	82
116	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. *Leukemia*, **2010**, 24, 629-37	10.7	173
115	The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. *Leukemia*, **2010**, 24, 1700-12	10.7	66
114	Monoclonal free light chains can be found in heavy chain diseases. *Annals of Clinical Biochemistry*, **2010**, 47, 570-2	2.2	6
113	Novel treatment regimens for Waldenström's macroglobulinemia. *Expert Review of Hematology*, **2010**, 3, 339-50	2.8	13
112	Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. *Clinical Cancer Research*, **2010**, 16, 3260-9	12.9	56
111	Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. *Haematologica*, **2010**, 95, 745-51	6.6	42
110	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. *Lancet Oncology, The*, **2010**, 11, 934-41	21.7	384
109	Primary cutaneous localized amyloid elastosis. *American Journal of Dermatopathology*, **2010**, 32, 86-90	0.9	10
108	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. *Blood*, **2010**, 116, e12-7	2.2	39
107	BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). *Annals of Hematology*, **2010**, 89, 453-8	3	33
106	Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. *Annals of Hematology*, **2010**, 89, 803-11	3	28

105	The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. *European Journal of Haematology*, **2010**, 84, 266-70	3.8	7
104	Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. *Journal of Clinical Oncology*, **2009**, 27, 120-6	2.2	173
103	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. *Annals of Oncology*, **2009**, 20, 1303-17	10.3	171
102	Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. *Oral Diseases*, **2009**, 15, 382-7	3.5	54
101	High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. *Leukemia Research*, **2009**, 33, 1706-9	2.7	44
100	International prognostic scoring system for Waldenstrom macroglobulinemia. *Blood*, **2009**, 113, 4163-70	2.2	282
99	Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. *Journal of Experimental Medicine*, **2009**, 206, 3131-41	16.6	96
98	Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. *Blood*, **2009**, 114, 148-52	2.2	68
97	The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. *Tissue Antigens*, **2008**, 71, 548-51		3
96	Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?. *British Journal of Haematology*, **2008**, 140, 324-6	4.5	14
95	Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. *British Journal of Haematology*, **2008**, 141, 212-5	4.5	22
94	Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. *British Journal of Haematology*, **2008**, 142, 766-74	4.5	43
93	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. *Haematologica*, **2008**, 93, 560-5	6.6	72
92	Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. *Blood*, **2008**, 112, 2709-12	2.2	184
91	The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. *Haematologica*, **2008**, 93, 1797-805	6.6	33
90	Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting. *Transplantation*, **2008**, 86, 983-90	1.8	4
89	New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. *Blood*, **2007**, 110, 2586-92	2.2	365
88	Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. *Cytotherapy*, **2007**, 9, 14-22	4.8	24

87	Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia. *Clinical Lymphoma and Myeloma*, **2007**, 7, 573-9		8
86	Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. *Leukemia*, **2007**, 21, 201-6	10.7	241
85	Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. *Leukemia*, **2007**, 21, 215-21	10.7	195
84	6q deletion in Waldenstrm macroglobulinemia is associated with features of adverse prognosis. *British Journal of Haematology*, **2007**, 136, 80-6	4.5	85
83	Functional class switch recombination may occur 'in vivo' in Waldenstrm macroglobulinaemia. *British Journal of Haematology*, **2007**, 136, 114-6	4.5	12
82	Molecular biology of myeloma. *Clinical and Translational Oncology*, **2007**, 9, 618-24	3.6	11
81	Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrm's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. *Haematologica* , **2007**, 92, 635-42	6.6	48
80	Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. *Haematologica*, **2007**, 92, 315-22	6.6	68
79	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. *Blood*, **2007**, 110, 3112-21	2.2	123
78	Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. *Thrombosis Research*, **2007**, 119, 691-8	8.2	4
77	Clinical Efficacy of Bortezomib Based Therapy in Plasma Cell Leukemias.. *Blood*, **2007**, 110, 2726-2726	2.2	1
76	A PETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma (MM): Identification of two populations with different outcomes. *Journal of Clinical Oncology*, **2007**, 25, 8021-8021	2.2	4
75	Prognostic Factors and Classification in Multiple Myeloma. *Translational Medicine Series*, **2007**, 115-140		
74	Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. *Hematological Oncology*, **2006**, 24, 205-11	1.3	8
73	Thalidomide in multiple myeloma. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 195-213	4	11
72	Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2006**, 6, 380-3		98
71	Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma. *Journal of Molecular Diagnostics*, **2006**, 8, 364-70	5.1	1
70	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. *Blood*, **2006**, 108, 2165-72	2.2	333

69	Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. *Blood Coagulation and Fibrinolysis*, **2006**, 17, 23-8	1	25
68	International Prognostic Scoring System (IPSS) for Waldenstro m Macroglobulinemia (WM).. *Blood* , **2006**, 108, 127-127	2.2	18
67	Influence of GST Gene Polimorphisms in the Develovement of Liver Sinusoidal Obstructive Syndrome in Patients with Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.. *Blood*, **2006**, 108, 3084-3084	2.2	
66	The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma. *Haematologica*, **2006**, 91, 1551-4	6.6	9
65	Cell cycle analysis of Waldenstrom's macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2005**, 5, 250-2		4
64	Prognostic features of multiple myeloma. *Best Practice and Research in Clinical Haematology*, **2005**, 18, 569-83	4.2	23
63	Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. *Leukemia*, **2005**, 19, 713-20	10.7	47
62	Incomplete DJH rearrangements. *Methods in Molecular Medicine*, **2005**, 113, 165-73		5
61	Analysis of methylation pattern in multiple myeloma. *Acta Haematologica*, **2005**, 114 Suppl 1, 23-6	2.7	11
60	Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. *Haematologica*, **2005**, 90, 906-13	6.6	19
59	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. *Haematologica*, **2005**, 90, 1365-72	6.6	122
58	FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. *The Hematology Journal*, **2004**, 5, 239-46		29
57	Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. *Journal of Clinical Oncology*, **2004**, 22, 1664-73	2.2	53
56	Bone remodelation markers are useful in the management of monoclonal gammopathies. *The Hematology Journal*, **2004**, 5, 480-8		15
55	Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. *British Journal of Haematology*, **2004**, 127, 159-64	4.5	62
54	Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. *Bone Marrow Transplantation*, **2004**, 33, 579-87	4.4	5
53	The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. *Leukemia*, **2004**, 18, 856-63	10.7	142
52	Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. *International Journal of Cancer*, **2004**, 112, 884-9	7.5	38

51	Myeloma: update on supportive care strategies. *Current Treatment Options in Oncology*, **2003**, 4, 247-58	5.4	3
50	Reply to Yanamandra et al. *British Journal of Haematology*, **2003**, 120, 1096-1096	4.5	
49	Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. *Leukemia*, **2003**, 17, 1051-7	10.7	24
48	Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. *Leukemia*, **2003**, 17, 1124-9	10.7	48
47	Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. *Leukemia*, **2003**, 17, 1398-403	10.7	31
46	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. *Leukemia*, **2003**, 17, 2257-317	10.7	2404
45	Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. *Blood*, **2003**, 101, 4695-700	2.2	112
44	Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. *British Journal of Haematology*, **2002**, 117, 890-2	4.5	22
43	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. *British Journal of Haematology*, **2002**, 118, 239-42	4.5	47
42	Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. *British Journal of Haematology*, **2002**, 118, 1034-40	4.5	68
41	Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. *British Journal of Haematology*, **2002**, 119, 883-4	4.5	12
40	The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. *The Hematology Journal*, **2002**, 3, 43-8		49
39	Association of CD4+/CD56+/CD57+/CD8+(dim) large granular lymphocytic leukemia, splenic B-cell lymphoma with circulating villous lymphocytes, and idiopathic erythrocytosis. *Annals of Hematology* , **2001**, 80, 685-90	3	14
38	Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. *British Journal of Haematology*, **2001**, 114, 99-103	4.5	44
37	Waldenstrm macroglobulinaemia: presenting features and outcome in a series with 217 cases. *British Journal of Haematology*, **2001**, 115, 575-82	4.5	178
36	Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. *Bone Marrow Transplantation*, **2001**, 28, 665-72	4.4	11
35	Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. *Leukemia*, **2001**, 15, 121-7	10.7	17
34	Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. *Leukemia*, **2001**, 15, 406-14	10.7	84

33	Debate round-table: comments concerning chimerism studies. *Leukemia*, **2001**, 15, 1986-8	10.7	11
32	p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. *The Hematology Journal*, **2001**, 2, 146-9		25
31	Expression of high amounts of the CD117 molecule in a case of B-cell non-Hodgkin's lymphoma carrying the t(14:18) translocation. *American Journal of Hematology*, **2000**, 63, 226-9	7.1	12
30	Two new 3? PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia **2000**, 27, 35-43		18
29	De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. *Leukemia*, **2000**, 14, 183-7	10.7	50
28	The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. *Leukemia*, **2000**, 14, 1493-9	10.7	15
27	Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. *Clinical Biochemistry*, **2000**, 33, 415-8	3.5	5
26	Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. *The Hematology Journal*, **2000**, 1, 28-36		86
25	Two new 3? PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia **2000**, 27, 35		3
24	Low frequency of the TEL/AML1 fusion gene in acute lymphoblastic leukaemia in Spain. *British Journal of Haematology*, **1999**, 107, 667-9	4.5	34
23	Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. *American Journal of Hematology*, **1999**, 60, 191-5	7.1	46
22	Treatment of multiple myeloma. *Haematologica*, **1999**, 84, 36-58	6.6	48
21	Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma. *Haematologica*, **1999**, 84, 328-35	6.6	19
20	The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. *Haematologica*, **1999**, 84, 405-12	6.6	76
19	Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategies. *Haematologica*, **1999**, 84, 779-84	6.6	28
18	Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. *American Journal of Pathology*, **1998**, 152, 1655-65	5.8	137
17	Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. *Blood*, **1998**, 91, 3366-71	2.2	21
16	Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype. *Haematologica*, **1998**, 83, 209-16	6.6	13

15	Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. *Leukemia*, **1997**, 11, 1915-20	10.7	25
14	BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. *Bone Marrow Transplantation*, **1997**, 20, 451-8	4.4	113
13	Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. *Hematology and Cell Therapy*, **1997**, 39, 223-7		7
12	Immunophenotypic Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia. *Hamatologie Und Bluttransfusion*, **1997**, 321-327		
11	Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation. *European Journal of Haematology*, **1996**, 56, 181-3	3.8	8
10	DNA cell content studies in multiple myeloma. *Leukemia and Lymphoma*, **1996**, 23, 33-41	1.9	29
9	Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. *British Journal of Haematology*, **1996**, 93, 81-8	4.5	62
8	Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. *British Journal of Haematology*, **1996**, 95, 489-93	4.5	64
7	In vitro autonomous proliferation in ANLL: clinical and biological significance. *Leukemia Research*, **1995**, 19, 411-6	2.7	5
6	Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leon□ (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. *British Journal of Haematology*, **1995**, 90, 106-12	4.5	68
5	Immunophenotype and DNA cell content in multiple myeloma. *Best Practice and Research: Clinical Haematology*, **1995**, 8, 735-59		47
4	A new staging system for multiple myeloma based on the number of S-phase plasma cells. *Blood*, **1995**, 85, 448-55	2.2	20
3	A new staging system for multiple myeloma based on the number of S- phase plasma cells. *Blood*, **1995**, 85, 448-455	2.2	100
2	A new staging system for multiple myeloma based on the number of S- phase plasma cells. *Blood*, **1995**, 85, 448-455	2.2	3
1	A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. *Cytometry*, **1994**, 17, 332-9		61